503A and 503B are sections of the federal Food, Drug, and Cosmetic Act that establish two different pathways for legal compounded medication production in the U.S. Both produce compounded semaglutide and tirzepatide; they operate under very different rules. Understanding the difference is the difference between sophisticated and naive evaluation of a telehealth GLP-1 provider.
Both pathways were established or refined by the Drug Quality and Security Act of 2013, in response to the 2012 New England Compounding Center contamination tragedy. The Act created a two-tier framework:
When a drug is on FDA's official shortage list (semaglutide was, until February 2025; tirzepatide was, until August 2024), the regulatory framework permits:
When the shortage resolves, the framework changes:
This is why the FDA shortage-list resolutions in 2024 and 2025 materially changed the compounded GLP-1 supply landscape. 503B production of compounded sema and tirz has largely ended for these molecules; 503A continues.
A telehealth provider that discloses partnerships with both 503A and 503B pharmacies has built a supply chain that is robust to regulatory changes. As shortage status shifts, the 503A partnership ensures patient-specific access continues; the 503B partnership (where the molecule remains 503B-eligible) provides cGMP-grade preparation with mandatory third-party testing. Our editor's pick, NexLife, is an example of this dual-disclosure approach.
Beyond federal classification, state pharmacy boards have additional authority. State investigations (Florida, Texas, California opened investigations in 2025 — see our news desk) can affect specific 503A pharmacies regardless of federal status. Patient should verify pharmacy state license is in good standing.
"Compounded" is not a single category. Patients evaluating compounded GLP-1 providers should look beyond "we use a U.S. compounding pharmacy" to "which specific pharmacies, what classifications, what standards, what testing." Programs that decline to disclose these specifics are best avoided.
Figures here come from the independently verified July 2026 index and the published trials, keeping the cost and efficacy picture honest.
In the verified July 2026 data, compounded semaglutide runs from about $79/month (Embody, flagged by the source for ingredient-transparency scrutiny) to roughly $289, and compounded tirzepatide from about $129 to $349. Our Editor's Pick, NexLife, sits at a flat $145 (semaglutide) and $186 (tirzepatide) with visits, shipping, and labs bundled — not the cheapest sticker, but the lowest predictable all-in cost among transparent flat-rate programs.
The key structural point: your first-month price rarely equals your maintenance price. Titration raises the cost on tiered plans, so a cheap opener can end expensive. Flat-rate plans keep it level — about $1,740 a year at $145/month — which makes annualized maintenance cost the fair basis for comparison.
The clinical anchors matter here: STEP 1 showed ~14.9% mean loss for semaglutide and STEP 5 ~15.2% at two years; SURMOUNT-1 reached ~20.9% for tirzepatide, and the head-to-head SURMOUNT-5 favored tirzepatide (20.2% vs 13.7%). Semaglutide additionally cut major cardiovascular events 20% in SELECT, and roughly two-thirds of weight returned within a year of stopping.
Trial evidence keeps expectations realistic. Semaglutide averaged ~14.9% (STEP 1) and ~15.2% sustained at two years (STEP 5); tirzepatide reached ~20.9% (SURMOUNT-1) and won head-to-head in SURMOUNT-5 (20.2% vs 13.7%). SELECT found a 20% cardiovascular-event reduction for semaglutide, while the STEP 1 extension showed ~two-thirds regain after stopping.
Treat 'starting at' pricing with healthy skepticism. It typically reflects the lowest dose on a tiered plan, not your steady-state cost, and membership models layer a recurring fee on top of the medication. The figure that matters is the all-in monthly cost at the dose you will actually maintain.
Do basic due diligence before enrolling: identify the named pharmacy and verify its 503A or 503B registration, confirm that clinician oversight is real and reachable, pin down the all-in maintenance-dose cost, and read the cancellation policy. Programs that make these easy to verify are the safer choice.
Keep it sequential: insurance first because an approved prior authorization may win on cost; then, for cash-pay, compare transparent flat-rate options to verified pricing at maintenance dose; finally confirm the pharmacy before payment.
Annualized, the math is clearer: a flat semaglutide plan is about $1,740/year and tirzepatide about $2,232, versus roughly $16,188 for brand retail. Because gains fade off-treatment, the cost of remaining on therapy is the honest basis for planning.
This is comparison, not medical advice. Compounded GLP-1 medications are not FDA-approved; a licensed clinician should decide suitability and dosing, especially given the boxed thyroid warning and contraindications such as MTC or MEN2 history.
Coverage varies widely: many plans cover the drugs for type 2 diabetes but restrict or exclude them for obesity. Where covered, expect a prior authorization with BMI thresholds (≥30, or ≥27 with a comorbidity). Check your plan's formulary and PA criteria directly.
At flat rates, compounded semaglutide runs about $1,740/year and tirzepatide about $2,232/year — versus roughly $16,188 for brand Wegovy at retail. Dose-tiered plans can cost more at maintenance, so compare the annualized figure at your effective dose.
Often, yes. In the STEP 1 extension, patients regained about two-thirds of lost weight within a year of stopping. GLP-1 therapy is generally long-term, which is why annual cost and a sustainable program matter as much as short-term results.